NCT01161563 - Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration | Biotech Hunter

Enrollment

118

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions

Prostate Cancer

Interventions

DRUG

Triptorelin pamoate

Triptorelin pamoate for injectable suspension 22.5 mg administered as a single intramuscular injection in either buttock

DRUG

Leuprolide acetate

Leuprolide acetate for injectable suspension 45 mg administered as a single subcutaneous injection in the upper- or mid-abdominal area.

Trial Locations (16)

Watson Investigational Site, Homewood

Watson Investigational Site, Daytona Beach

Watson Investigational Site, Orange City

Watson Investigational Site, Coeur d'Alene

Watson Investigational Site, Carmel

Watson Investigational Site, Jeffersonville

Watson Investigational Site, Shreveport

Watson Investigational Site, Las Vegas

Watson Investigational Site, Mount Laurel

Watson Investigational Site, Voorhees Township

Watson Investigational Site, Albany

Watson Investigational Site, Syracuse

Watson Investigational Site, Lancaster

Watson Investigational Site, Myrtle Beach

Watson Investigational Site, Dallas

Watson Investigational Site, Norfolk